MedTrace Logo

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

NCT04445454 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-09

No results posted yet for this study

Summary

The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.

Conditions

  • Coronavirus Infection

Interventions

BIOLOGICAL

Mesenchymal stromal cells

Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.

Sponsors & Collaborators

  • University of Liege

    lead OTHER

Principal Investigators

  • Yves Beguin, MD,PhD · Centre Hospitalier Universitaire de Liege

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445454 on ClinicalTrials.gov